Synapse - Works

Results (2683)

Phase II study of depsipeptide (DEP) in radioiodine (RAI)-refractory metastatic nonmedullary thyroid carcinoma

Meeting Abstract

Sherman, E. J.; Fury, M. G.; Tuttle, R. M.; Ghossein, R.; Stambuk, H.; Baum, M.; Lisa, D.; Su, Y. B.; Shaha, A.; Pfister, D. G.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

A phase Ib trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in combination with docetaxel

Meeting Abstract

Riely, G. J.; Stoller, R.; Egorin, M.; Solit, D.; Dunbar, J.; Savage, A.; Walker, J.; Grayzel, D.; Ross, R.; Weiss, G. J.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Characteristics of first relapse in stage III melanoma patients with no evidence of disease (NED): Guidelines for follow-up

Meeting Abstract

Romano, E.; Scordo, M.; Chapman, P.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Discovery of the methylation of the metastasis suppressor gene KiSS-1 in bladder cancer

Meeting Abstract

Sanchez-Carbayo, M.; Orenes, E.; Gil, M.; Piulats, J. M.; Alvarez, M.; Bellmunt, J.; Palou, J.; Cordon-Cardo, C.; Ecke, T.; Lopez-Beltran, A.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: New data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, NSAPB C-06 and C-07, and C89803

Meeting Abstract

Sargent, D. J.; Yothers, G.; Van Cutsem, E.; Cassidy, J.; Saltz, L.; Wolmark, N.; Shi, Q.; Buyse, M.; de Gramont, A.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Prognostic value of quantitative image analysis (QIA) for determination of proliferative index in mantle cell lymphoma (MCL) treated with sequential chemotherapy followed by high-dose therapy and autologous stem cell rescue (HDT/ASCR)

Meeting Abstract

Schaffel, R.; Hedvat, C.; Teruya-Feldstein, J.; Portlock, C. S.; Moskowitz, C. H.; Zelenetz, A. D.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Safety and efficacy of AMG 655 plus modified FOLFOX6 (mFOLFOX6) and bevacizumab (B) for the first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC)

Meeting Abstract

Saltz, L.; Infante, J.; Schwartzberg, L.; Stephenson, J.; Rocha-Lima, C.; Galimi, F.; Dillingham, K.; Hsu, M.; Wiezorek, J.; Fuchs, C.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC)

Meeting Abstract

Rixe, O.; Dutcher, J.; Motzer, R.; Wilding, G.; Stadler, W. M.; Garrett, M.; Pithavala, Y.; Kim, S.; Tarazi, J.; Rini, B. I.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

The influence of margin width and volume of disease near margin on benefit of radiation therapy after breast-conserving surgery for DCIS: Results of long-term follow-up

Meeting Abstract

Rudloff, U.; Brogi, E.; McCormick, B.; Brockway, J. P.; Goldberg, J. I.; Wynveen, C. A.; Reiner, A. S.; Patil, S.; Van Zee, K. J.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

PLX4032, a highly selective (V600E)BRAF kinase inhibitor: Clinical correlation of activity with pharmacokinetic and pharmacodynamic parameters in a phase I trial

Meeting Abstract

Puzanov, I.; Nathanson, K. L.; Chapman, P. B.; Xu, X.; Sosman, J. A.; McArthur, G. A.; Ribas, A.; Kim, K. B.; Grippo, J. F.; Flaherty, K. T.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save